NCT05128344撤回3 期
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms
Amzell41 个研究点 分布在 8 个国家开始时间: 2023年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 41
- 主要终点
- Proportion of Participants with Resolution of Hypsarrhythmia or Significant Abnormality Compatible with Infantile Spasms (IS) as Assessed by Video EEG at Day 14
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy of AMZ002 compared to Vigabatrin in participants with newly diagnosed infantile spasms (IS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Months 至 24 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has been diagnosed with IS within 6 weeks prior to Screening. Diagnostic criteria include both clinical spasms and an EEG pattern consistent with hypsarrhythmia or significant abnormality compatible with IS
- •Participant has normal renal function as defined by an estimated glomerular filtration rate (eGFR) greater than [>] 60 milliliter/minute (mL/min)/1.73 m^2, calculated as eGFR = 0.413 × (height [Centimeter (cm)]/serum creatinine [milligrams per deciliter {mg/dL}])
- •Participant's legally authorized representative (that is [i.e.], parent or guardian) must provide written informed consent obtained per Institutional Review Board (IRB) policy and requirements, consistent with the International Council for Harmonisation (ICH)
- •Participant's parent/guardian is able to understand and willing to comply with study procedures and restrictions
排除标准
- •Participant has been diagnosed with tuberous sclerosis
- •Participant has acute illness considered clinically significant by the Investigator within 30 days prior to Screening
- •Participant has a diagnosis of recent systemic fungal infection; history of ocular herpes simplex; history of or current peptic ulcer; uncontrolled hypertension or congestive heart failure; or any other condition that would be significantly impacted by the study drug
- •Participant has a preplanned surgery or procedure(s) that would interfere with the conduct of the study
- •Participant has received any prior treatment for IS
- •Participant has been previously treated with adrenocorticotropic hormone (ACTH), corticosteroids, or Vigabatrin for seizures;
- •Participant has been previously treated with a course of corticosteroids for an indication other than seizures within 30 days prior to Screening
- •Participant has a known or suspected allergy to ACTH or Vigabatrin or any component of AMZ002 or Vigabatrin
- •Participant has used any other investigational drug within 30 days or 5 half-lives prior to the first dose of AMZ002 or Vigabatrin (whichever is longer)
- •Participant' s parent/guardian is unable to provide written informed consent and/or to complete the daily diary
- •Participant has any other disease, condition, or therapy that, in the opinion of the Investigator, might compromise safety or compliance, preclude the participant from successfully completing the study, or interfere with the interpretation of the results
研究组 & 干预措施
AMZ002
Experimental
干预措施: AMZ002 injectable solution, 0.5mg/mL (Drug)
Vigabatrin
Active Comparator
干预措施: Vigabatrin, oral (Drug)
结局指标
主要结局
Proportion of Participants with Resolution of Hypsarrhythmia or Significant Abnormality Compatible with Infantile Spasms (IS) as Assessed by Video EEG at Day 14
时间窗: At Day 14
Proportion of Participants with Absence of Clinical Spasms as Assessed by Video Electroencephalogram (EEG) at Day 14
时间窗: At Day 14
次要结局
- Time from Treatment Initiation to Absence of Clinical Spasms as Assessed by Parent/Guardian Diary(Baseline up to Day 58)
- Proportion of Participants with Absence of Clinical Spasms as Assessed by Parent/Guardian Diary at Day 14(At Day 14)
- Proportion of Participants with Recurrence of Clinical Spasms After Initial Response as Assessed by Video EEG/ by Parent/Guardian Diary(From Day 14 up to Day 58)
- Time from Initial Response to Recurrence of Clinical Spasms(From Day 14 up to Day 58)
研究者
研究点 (41)
Loading locations...
相似试验
终止
2 期
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)NCT00666497Mirati Therapeutics Inc.6
终止
3 期
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedAcute Myeloid LeukemiaNCT04778397Gilead Sciences258
终止
3 期
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05079230Gilead Sciences378
进行中（未招募）
3 期
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT05502237Gilead Sciences1,021
已完成
3 期
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)Chronic Hepatitis CNCT02105688Merck Sharp & Dohme LLC301